Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FMEH3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $115,993
Award facts
- Contract value 100% obligated
- $115,993.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $115,993.32 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Trikafta 100-50-75 mg/150 mg tablets. The delivery order, issued on January 28, 2026, with an ultimate completion date of January 29, 2026, was not issued under any set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group serves as a critical supplier within the Department of Defense pharmaceutical supply chain and operates without identified subcontractors.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply to military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, and authorizes the DLA to issue firm fixed-price delivery orders for an extensive range of branded and generic prescription medications, biologics, and medical consumables. This delivery order exemplifies the ongoing execution of the PPV-G GEN V program, positioning DMS Pharmaceutical Group as a key regional prime vendor contractor supporting Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FMEH3?
SPE2DR26FMEH3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FMEH3 worth?
The government has obligated $115,993 on SPE2DR26FMEH3.
Is contract SPE2DR26FMEH3 an order under another contract?
Yes. SPE2DR26FMEH3 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEH3 competed?
The extent of competition for SPE2DR26FMEH3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award